As of January 23, 2025, Rallybio (RLYB) has a market cap of $36.185 million USD. According to our data, Rallybio is ranked No.8336 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 23, 2025 | $36.19 M |
-9.15%
|
Dec 31, 2024 | $39.83 M |
-59.83%
|
Dec 29, 2023 | $99.16 M |
-63.62%
|
Dec 30, 2022 | $0.27 B |
-31.13%
|
Dec 31, 2021 | $0.40 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
BioMarin Pharmaceutical
BMRN
|
$11.82 B |
0.000 M
|
USA
|
Ultragenyx
RARE
|
$3.97 B |
0.000 M
|
USA
|
Vertex Pharmaceuticals
VRTX
|
$110.22 B |
0.001 M
|
USA
|
Sarepta Therapeutics
SRPT
|
$11.09 B |
0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.77 B |
-0.000 M
|
Switzerland
|
Editas Medicine
EDIT
|
$0.11 B |
-0.000 M
|
USA
|
Intellia Therapeutics
NTLA
|
$1.12 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.24 B |
-0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.39 B |
-0.000 M
|
USA
|
Rocket Pharmaceuticals
RCKT
|
$1.11 B |
-0.000 M
|
USA
|
Beam Therapeutics
BEAM
|
$2.19 B |
0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$38.13 M |
0.000 M
|
USA
|
Market Cap | = | RLYB Stock Price | * | RLYB Shares Outstanding |
= | $0.87 | * | 41.49 M | |
= | $36.19 M |